What is the standard R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen and dosing for adult diffuse large B‑cell lymphoma, and how should it be adjusted for patients ≥65 years or with comorbidities?

R-CHOP Dosing and Management for Diffuse Large B-Cell Lymphoma

Standard R-CHOP-21 Regimen

R-CHOP-21 administered every 21 days is the definitive first-line treatment for CD20-positive diffuse large B-cell lymphoma, with 6–8 cycles depending on age and risk stratification. 1

Exact Dosing per Cycle (Day 1 Every 21 Days)

• Rituximab: 375 mg/m² IV on day 1 2
• Cyclophosphamide: 750 mg/m² IV on day 1 2
• Doxorubicin: 50 mg/m² IV on day 1 2
• Vincristine: 1.4 mg/m² IV on day 1 (maximum total dose capped at 2 mg regardless of body surface area) 3, 2
• Prednisone: 40–100 mg/m² (or 100 mg flat dose) orally on days 1–5 2

Age-Based Treatment Algorithms

Patients Aged 60–80 Years

Administer eight cycles of R-CHOP-21 with eight total rituximab infusions, regardless of IPI risk category. 4, 1, 5

• Consolidation radiotherapy after chemotherapy provides no survival benefit in this age group and should not be used 4, 1
• If R-CHOP-14 is mistakenly chosen, six cycles with eight rituximab doses are sufficient, though R-CHOP-14 offers no survival advantage over R-CHOP-21 4, 3, 2

Patients Aged 18–60 Years with Low Risk (aaIPI ≤1)

Give six cycles of R-CHOP-21 with six rituximab infusions. 4, 1, 3

• For low-intermediate risk or bulky disease, add involved-field radiotherapy to sites of previous bulk after completing six cycles 3, 5

Patients Over 80 Years

Perform a comprehensive geriatric assessment measuring functional status, comorbidity burden, cognitive function, and nutritional status before initiating therapy. 1, 5

• Fit patients: administer standard R-CHOP-21 up to age 80 4, 1
• Patients with significant comorbidities: use R-miniCHOP (rituximab with 50–70% dose reduction of cyclophosphamide and doxorubicin) 5, 6, 7
  • 70% dose reduction (R-70%CHOP) achieves 3-year progression-free survival of 64%, comparable to full-dose in younger patients 6
  • For patients ≥80 years, 58% dose reduction (7/12 dose) maintains efficacy while reducing toxicity 7
• Cardiac dysfunction: substitute doxorubicin with etoposide or liposomal doxorubicin, or omit after initial cycles 5

Critical Pre-Treatment Requirements

Tumor Lysis Syndrome Prevention

For patients with high tumor burden (elevated LDH, bulky disease >10 cm, or high white blood cell count), administer oral prednisone 100 mg daily for 5–7 days as pre-phase treatment before starting full R-CHOP. 1, 3, 5

• Provide aggressive hydration and allopurinol 300 mg daily (or rasburicase 0.2 mg/kg IV for highest-risk patients) 1
• Do not delay definitive chemotherapy beyond 7 days after completing pre-phase 1

Mandatory Screening

Screen all patients for hepatitis B surface antigen and core antibody before rituximab; HBsAg-positive patients require prophylactic entecavir 0.5 mg daily throughout treatment and for 12 months after. 1, 3

• Also screen for HIV and hepatitis C 4, 1, 3
• Measure baseline left ventricular ejection fraction; LVEF <50% mandates doxorubicin dose reduction or substitution 3
• Obtain complete blood count, lactate dehydrogenase, and uric acid to assess tumor burden 4, 3

Dose Management and Supportive Care

Growth Factor Support

Administer primary prophylactic G-CSF (filgrastim 5 mcg/kg or pegfilgrastim 6 mg) starting 24–72 hours after chemotherapy to all patients >65 years and to any patient receiving curative-intent therapy. 1, 3, 5

• G-CSF prevents febrile neutropenia and avoids the need for dose reductions 4, 1

Dose Intensity Principles

Avoid routine dose reductions for hematologic toxicity; maintain full chemotherapy doses to preserve curative intent. 4, 1, 3, 5

• Dose reductions are reserved only for life-threatening toxicity (grade 4 non-hematologic events or prolonged grade 4 neutropenia with infection despite G-CSF) 1, 3
• Use full weight-based dosing in obese patients without arbitrary caps (except vincristine 2 mg maximum) 3

CNS Prophylaxis Algorithm

High-Risk Criteria Requiring CNS Prophylaxis

Administer CNS prophylaxis for patients with high-intermediate or high IPI risk (score ≥3), ≥2 extranodal sites, elevated LDH, or involvement of testis, kidney, adrenal glands, or bone marrow. 4, 1, 3, 5

Preferred CNS Prophylaxis Method

Use intravenous high-dose methotrexate 3–3.5 g/m² every 2–3 weeks for 2–4 doses; intrathecal methotrexate alone is suboptimal and should not be used as sole prophylaxis. 4, 1, 3, 5

Testicular Lymphoma

Testicular DLBCL mandates CNS prophylaxis with high-dose IV methotrexate plus contralateral testicular irradiation (30 Gy) for stage I–II disease. 4, 1, 5

Response Assessment

Interim Evaluation

Perform CT or PET-CT after 3–4 cycles (mid-treatment) to assess response and guide further management. 4, 1, 3

End-of-Treatment Assessment

Obtain PET-CT 6–8 weeks after completing all therapy to define complete remission using the Deauville 5-point scale (scores 1–3 indicate complete metabolic response). 1, 3

• If PET remains positive (Deauville 4–5) and will alter management, obtain histologic confirmation before declaring treatment failure 4, 1
• Repeat bone marrow biopsy at end of treatment only if marrow was involved at diagnosis 4, 1

Critical Pitfalls to Avoid

Do not use R-CHOP-14; a randomized trial of 1,080 patients showed no improvement in 2-year overall survival (82.7% vs 80.8%, HR 0.90, p=0.38) or progression-free survival (75.4% vs 74.8%, HR 0.94, p=0.59) compared to R-CHOP-21. 3, 2

Do not reduce chemotherapy doses after pre-phase treatment due to hematologic concerns unless life-threatening toxicity occurs; use prophylactic G-CSF instead. 1, 3, 5

Do not omit CNS prophylaxis in high-risk patients, particularly those with testicular involvement, as CNS relapse is fatal. 4, 1, 5

Do not skip comprehensive geriatric assessment in patients >80 years before committing to full-dose therapy; functional status predicts tolerance better than chronologic age. 1, 5

Do not add consolidation radiotherapy to 6–8 cycles of R-CHOP in patients 60–80 years with localized disease; no benefit has been demonstrated in the rituximab era. 4, 1